Σύγκριση μεθόδων

	Εξέταση Γνωστικών Λειτουργιών Addenbrooke (ACE)	Κλίμακα Αξιολόγησης Νόσου Alzheimer-Γνωστική Λειτουργία
Πεδίο	Νευροψυχολογία	Νευροψυχολογία
Οικογένεια	Process / pipeline	Process / pipeline
Έτος προέλευσης	2000	1984
Δημιουργός	Padasalai Mathuranath	William Rosen
Τύπος	Clinician-administered comprehensive cognitive examination	Clinician-administered cognitive scale for Alzheimer's disease
Θεμελιώδης πηγή	Mathuranath, P. S., Nestor, P. J., Berrios, G. E., Rakowicz, W., & Hodges, J. R. (2000). A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology, 55(11), 1613-1620.	Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141(11), 1356-1364.
Εναλλακτικές ονομασίες	ACE, ACE-R, ACE-III, Addenbrooke Cognitive Examination	ADAS-Cog, ADAS-Cog14, ADAS-Cog13
Συναφείς	5	5
Σύνοψη	The Addenbrooke's Cognitive Examination (ACE) is a brief yet comprehensive clinician-administered cognitive battery designed to assess multiple cognitive domains and differentiate between types of dementia. Originally developed by Mathuranath and colleagues at Cambridge University in 2000, the ACE was created to address limitations of single-domain screening tools. The revised version (ACE-R, 2006) and further refined version (ACE-III, 2013) provide updated norms and improved sensitivity. The ACE-R and ACE-III are particularly valuable for distinguishing Alzheimer's disease from frontotemporal dementia.	The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) is a clinician-administered cognitive assessment instrument designed specifically to measure cognitive decline in Alzheimer's disease. Developed by Rosen, Mohs, and Davis in 1984 and published in the American Journal of Psychiatry, the ADAS-Cog has become the gold standard outcome measure in pharmaceutical trials of antidementia drugs. It is sensitive to disease progression and capable of detecting cognitive change over periods as brief as 6–12 months.